|[April 23, 2012]
BSD Medical Announces Study Featuring MicroThermX® Microwave Ablation System Presented at Society of Interventional Radiology (SIR) Conference Demonstrates Advantages of Microwave Ablation
SALT LAKE CITY --(Business Wire)--
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, announced today that a scientific poster presented at the
Society of Interventional Radiology (SIR) conference, featuring data
generated using the MicroThermX® Microwave Ablation System
(MicroThermX®), demonstrated a significant advantage for
MicroThermX® microwave ablation. The study, "Impact of
Variation in Portal Venous Blood Flow on the Size of Radiofrequency and
Microwave Ablation Lesions," was conducted by Gerald D. Dodd, III, MD,
Nicolas A. Dodd, and Anthony C. Lanctot, MS, Department of Radiology,
University of Colorado, School of Medicine. Dr. Gerald D. Dodd, one of
the pioneers in Radiofrequency (RF) ablation, presented the data from
the in-vitro study, which was designed to assess the impact of
variations in blood flow on ablation zones produced using the microwave
MicroThermX® compared to a commercially available RF system.
The presentation received an award at the SIR conference.
"Microwave ablation is able to deliver a predictable and reproducible
heating pattern that is not influenced by physiological changes in blood
flow in the liver," said Dr. Gerald D. Dodd. "This is a significant
clinical advantage over RF ablation, which is significantly impacted by
physiological changes in blood flow in the liver. Predictable and
reproducible ablations are a critical element of treatment planning for
ablation. Not knowing the size of the ablation that you are going to get
when treating a liver tumor leads to both over-treatment and
under-treatment. Over-treatment poses the risk of injury to adjacent
vital structures, and under-treatment means you didn't 'kill' the tumor.
The predictable and reproducible performance of microwave ablation
should translate to improved clinical results for cancer patients."
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services
systems to treat cancer and benign diseases using heat therapy delivered
using focused radiofrequency (RF) and microwave energy. BSD's product
lines include both hyperthermia and ablation treatment systems. BSD's
hyperthermia cancer treatment systems, which have been in use for many
years in the United States, Europe and Asia, are used to treat certain
tumors with heat (hyperthermia) while increasing the effectiveness of
other therapies such as radiation therapy. BSD's microwave ablation
system has been developed as a stand-alone therapy to ablate and destroy
soft tissue. The Company has developed extensive intellectual property,
multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company's products have
received regulatory approvals in the United States, Europe and China.
For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts
are forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
subject to risks and uncertainties detailed in the Company's filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date on which such statements are made,
and the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date.
[ Back To TMCnet.com's Homepage ]